Meta-analysis: Somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis

Journal of Gastroenterology

Volumn 45, Issue 8, 2010, Pages 885-895

  Omata, Fumio ^a,b,f   Deshpande, Gautam ^b,e   Tokuda, Yasuharu ^c   Takahashi, Osamu ^a,b   Ohde, Sachiko ^b   Carr Locke, David L ^d   Jacobs, Joshua L ^e   Mine, Tetsuya ^a   Fukui, Tsuguya ^a,b  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b St Luke's Life Science Institute   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Octreotide; Post ERCP pancreatitis; Somatostatin

Indexed keywords

GASTROINTESTINAL AGENT; HORMONE; OCTREOTIDE; SOMATOSTATIN;

ACUTE DISEASE; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; META ANALYSIS; PANCREATITIS; STATISTICAL MODEL;

ACUTE DISEASE; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HORMONES; HUMANS; MODELS, STATISTICAL; OCTREOTIDE; PANCREATITIS; SOMATOSTATIN;

EID: 79952031898     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0234-4     Document Type: Article

References (53)

1. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845-64. (Pubitemid 38879313)
2. Bordas JM, Toledo V, Mondelo F, Rodes J. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Horm Res. 1988;29:106-8.
3. Saari A, Kivilaakso E, Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm. 1988;2:271-8. (Pubitemid 18064642)
4. Guelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc. 1991;37:44-7.
5. Persson B, Slezak P, Efendic S, Haggmark A. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology. 1992;39:259-61.
6. Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Gines A, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998;47:230-4. (Pubitemid 28155343)
7. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-95.
8. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999;49:593-8. (Pubitemid 29227021)
9. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, et al. Can somatostatin prevent post- ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004;19:278-82. (Pubitemid 38338736)
10. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2:713-8. (Pubitemid 39013432)
11. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci. 1992;37:773-7.
12. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med. 1996;335:919-23. (Pubitemid 26314444)
13. Weiner GR, Geenen JE, Hogan WJ, Catalano MF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc. 1995;42:579-83.
14. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol. 1998;93:61-5. (Pubitemid 29065515)
15. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc. 2002;55:470-5.
16. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc. 2003;58:23-9. (Pubitemid 38208742)
17. Raptis S, Schlegel W, Lehmann E, Dollinger HC, Zoupas C. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism. 1978;27:1321-8. (Pubitemid 9014208)
18. Dollinger HC, Raptis S, Pfeiffer EF. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res. 1976;8:74-8.
19. Schlegel W, Raptis S, Harvey RF, Oliver JM, Pfeiffer EF. Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet. 1977;2:166-8.
20. Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, et al. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg. 1985;72:382-5. (Pubitemid 15034712)
21. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut. 2003;52: 1768-73. (Pubitemid 37510401)
22. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 2008;37:445-8.
23. Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992;87:1561-6.
24. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994;26:715-8.
25. Duvnjak M, Supanc V, Simicevic VN, Hrabar D, Troskot B, Smircic-Duvnjak L, et al. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica. 1999;53:115-8. (Pubitemid 30415475)
26. Hardt PD, Kress O, Fadgyas T, Doppl W, Schnell-Kretschmer H, Wusten O, et al. Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res. 2000;5:165-70.
27. Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc. 2006;64:726-31. (Pubitemid 44573121)
28. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007;65:624-32. (Pubitemid 46442832)
29. Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebocontrolled trials. J Gastroenterol Hepatol. 2007;22:977-83. (Pubitemid 47019864)
30. Zhang Y, Chen QB, Gao ZY, Xie WF. Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses. Aliment Pharmacol Ther. 2009;29:1155-64.
31. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9, W64.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
33. Juni P, Altman DG, Egger M. Meta-analysis in Stata. In: Egger M, Smith G, Altman D, editors. Systematic Reviews in Health Care British medical journal. 2003. p. 90.
34. Sterne J, Bradburn M, Egger M. Meta-analysis in Stata. In: Egger M, Smith G, Altman D, editors. Systematic Reviews in Health Care British medical journal. 2003. p. 200.
35. Duvnjak M, Supanc V, Šimičević V, Hrabar D, Troskot B, Smirčić-Duvnjak L, et al. A randomized, double-blind trial of the efficacy of octreotide acetate administration in the prevention of abdominal pain. Acta Clin Croat. 2001;40:9-13.
36. Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc. 1991;37:48-50.
37. Cicero GF, Laugier R, Sahel J, Manganaro M, Sarles H. Effects of somatostatin on clinical, biochemical and morphological changes following ERCP. Ital J Gastroenterol. 1985;17:265-8. (Pubitemid 16255082)
38. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51:1-7. (Pubitemid 30051601)
39. Börsch G, Bergbauer M, Nebel W, Sabin G. Effect of somatostatin on amylase level and pancreatitis rate following ERCP. Med Welt. 1984;35:109-12. (Pubitemid 14220870)
40. Testoni PA. Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastroenterol. 1988;20:70-3.
41. Flati G, Porowska B, Negro P, Flati D, Chiarinelli ML, Carboni M. Effect of somatostatin on the sequelae of endoscopic retrograde cholangiopancreatography. Rev Esp Enferm Apar Dig. 1988;74:17-9.
42. Deschner K, Kalloo A, Collen M, Cattau EL, Maher KA, et al. Somatostatin: an evaluation of its utility as adjunctive medication for ERCP. Gastrointest Endosc. 1989;35:A149.
43. Russo A, Virgilio C, Aprile G, Magnano A, Cosentino S. Influenza dell'octreotide sulla reazione pancraticaa indotta da colangiopancreatografia retrograda (Effect of octreotide on pancreatic reactions following ERCP). Giorn Ital End Dig. 1992;15:139-45. (Pubitemid 23041935)
44. Testoni PA, Lella F, Bagnolo F, Buizza M, Colombo E. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. Ital J Gastroenterol. 1994;26:431-6.
45. Baldazzi G, Conti C, Spotti EG, Arisi GP, Scevola M, Gobetti F, et al. Prevention of post-ERCP acute pancreatitis with octreotide. G Chir. 1994;15:359-62.
46. Testoni PA, Lella F, Bagnolo F, Caporuscio S, Cattani L, Colombo E, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas. 1996;13:61-5. (Pubitemid 26187771)
47. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology. 1998;45:248-52. (Pubitemid 28067562)
48. Benvenuti S, Zancanell L, Piazzi L, Comberlato M, Chilovi F, Germana B, et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesilate: a randomized placebo-controlled multicenter study. Dig Liver Dis. 2006;38:S15.
49. Badra G, Galal AS, Rowaisha I, Waked I, Moustafa MS, Saleh SM. Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patients with biliary obstruction. A randomized controlled trial. Hepatology 2000;32:163A.
50. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001;15:965-72. (Pubitemid 32578968)
51. Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2007;102:46-51. (Pubitemid 46072042)
52. Sofuni A, Maguchi H, Itoi T, Katanuma A, Hisai H, Niido T, et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol. 2007;5:1339-46. (Pubitemid 350019054)
53. Sutton A, Abrams K, Jones D, Sheldon T, Song F. Exploring between study heterogeneity. Methods for meta-analysis in medical research. New York: Wiley; 2000. p. 88.